INT250661

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.11
First Reported 2008
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 2
Total Number 2
Disease Relevance 0.82
Pain Relevance 0.08

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (EGF, ERBB2) plasma membrane (EGF, ERBB2) cell proliferation (ERBB2)
extracellular space (EGF) extracellular region (EGF) nucleus (ERBB2)
EGF (Homo sapiens)
ERBB2 (Homo sapiens)
Pain Link Frequency Relevance Heat
methotrexate 2 77.64 Quite High
Inflammation 2 5.00 Very Low Very Low Very Low
Taxol 2 5.00 Very Low Very Low Very Low
palliative 1 5.00 Very Low Very Low Very Low
Central nervous system 1 5.00 Very Low Very Low Very Low
cytokine 1 5.00 Very Low Very Low Very Low
metalloproteinase 1 5.00 Very Low Very Low Very Low
Kinase C 1 5.00 Very Low Very Low Very Low
headache 1 5.00 Very Low Very Low Very Low
antagonist 1 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Cancer 73 91.72 High High
Immunotherapy Of Cancer 2 79.44 Quite High
Disease 17 77.44 Quite High
Toxicity 10 74.52 Quite High
Adhesions 2 68.16 Quite High
Apoptosis 50 64.32 Quite High
Lung Cancer 4 61.60 Quite High
Breast Cancer 68 60.48 Quite High
Advanced Or Metastatic Breast Cancer 17 50.56 Quite High
Head & Neck Cancer 2 50.00 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Three of the four receptors comprise an extracellular amino-terminal domain to bind corresponding ligands (for example, EGF to EGFR; ligands to HER2 are not known) and an intracellular carboxyl-terminal domain lodging a tyrosine kinase with the exception of HER3.
EGF Binding (ligands) of HER2
1) Confidence 0.11 Published 2008 Journal Breast Cancer Res Section Body Doc Link PMC2575526 Disease Relevance 0.60 Pain Relevance 0
Since EGF-R and HER-2 heterodimerize to form functional signalling complexes, tyrosine-kinase inhibitors with dual specificity against HER-2 and EGF-R, such as lapatinib, have been investigated in phase I and II studies.
EGF-R Binding (heterodimerize) of HER-2
2) Confidence 0.05 Published 2010 Journal Head Neck Oncol Section Body Doc Link PMC2868849 Disease Relevance 0.22 Pain Relevance 0.08

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox